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Abstract
Purpose: To overcome the issue of reference values for DaTSCAN® requiring healthy controls,
we propose an original approach using scans from individuals with non-degenerative conditions
performed at one single center following the same acquisition protocol.
Procedures: From a cohort of 970 consecutive patients, we identified 182 patients with a clinical
diagnosis of non-degenerative parkinsonism or tremor and a visually normal DATSCAN®. Caudate
nucleus (C), putamen (P), and striatum (S) uptake values, C/P ratios, and asymmetry indexes (AI)
were calculated using semi-quantitative methods. Outcomes were assessed according to age and
gender, and reference limits were established using the percentile approach.
Results: A significant negative linear effect of age was found upon striatal nuclei uptake of 0.21–
0.22 per decade (6.8 %/decade for striatum), whereas a potential gender influence proved
unclear. Inferior reference limits were established at the 5th percentile. C/P ratios and AIs were
not influenced by age or gender, and superior reference limits were set at the 95th percentile.
Conclusions: We here propose a convenient approach to calculate site-specific reference limits
for DaTSCAN® outcomes not requiring scanning healthy controls. The method appears to yield
robust values that range within nearly identical limits as those obtained in healthy subjects.
Key words: SPECT, Reference values, Dopaminergic uptake, Gender, Age
Introduction
[123I]FP-CIT ([123I]ioflupane, DaTSCAN®, GE Healthcare,
Glattbrugg, Switzerland) single-photon emission computed to-
mography (SPECT) is one of the most widely used nuclear
medicine methods to assess the integrity of the nigrostriatal
pathway [1, 2]. It has proved highly valuable to distinguish
presynaptic degenerative forms of parkinsonism, notably
Parkinson’s disease (PD) and dementia with Lewy bodies
(DLB), from non-degenerative parkinsonian syndromes, such as
drug-induced parkinsonism (DIP) or psychogenic parkinsonisms
(PP), or from essential tremor and other atypical tremors [3–7].
However, the validity and clinical usefulness of this test rely
heavily on the method used to assess scan images and, thus far,
two approaches have been proposed, sometimes in combination.
First, a visual assessment using a grade 0 to 3 staging system
[8] is simple and does not involve specific software, yet thisCorrespondence to: Pierre R. Burkhard; e-mail: pierre.burkhard@hcuge.ch
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approach requires some expertise, may suffer from significant
intrarater and interrater variability, and may be inconclusive in
the not-so-rare cases with mild or questionable uptake deficits
[9]. Second, a more objective, semi-quantitative assessment
method providing handmade, region-of-interest (ROI)-based or
automated data has the advantage of well-defined and
comparative values [10–12]. Until recently, the validity of this
quantitative approach was mitigated by the lack of reference
limits obtained from healthy controls and by standardization
issues related to methodologies varying from one center to
another involving machine or protocol differences [9, 13–15].
A few years ago, a European multicenter group generated a
[123I]FP-CITSPECTdatabase obtained fromhealthy controls, and
results from this study were published two years ago [16, 17]. A
total of 139 scans performed in 13 different centers and covering a
large range of age and both genders equally were analyzed. Using
a stringent methodology, various outcomes were calculated and
authors were able to show, as other groups previously, that
dopamine transporters (DAT) availability seems to be increased in
women compared to men and that there is an age-related decline
of ligand uptake of 5.5 % per decade. While very valuable, this
approach showed also some limitations. First, despite efforts to
limit center-to-center variability, the use of 17 different SPECT
imaging systems of 11 different models in 13 different centers led
to some inconsistencies when comparing data. Second, this study
enrolled a relatively small sample of subjects per center, so that the
validity of data at the single center level might be problematic.
Finally, while this work was not specifically aimed at providing
reference limits that could separate normal and abnormal uptake
values, authors proposed formulas to calculate them.
We therefore decided to reappraise the issue of reference
values for [123I]FP-CIT SPECT using an original approach
designed to minimize intercenter variability. According to
these constraints, image acquisition was performed at one
single nuclear medicine center only, the same machine and
protocol were used for all subjects and we included a high
number of individuals with non-degenerative parkinsonism
and non-parkinsonian tremor, all conditions well known to be
associated with an unaltered [123I]FP-CIT SPECT [1, 3, 4, 18–
20]. The purpose of the present study was then to establish
reference values and limits for the caudate nucleus (C),
putamen (P), and striatum (S) and to address the influence of
age and gender upon DAT availability. We also analyzed other
parameters that might be useful to discriminate between normal
scans and the presence of degenerative parkinsonism at an
early stage, including the C/P ratio and the asymmetry indexes
(AIs) between right and left striatal structures.
Materials and Methods
Patients
As shown on Fig. 1 detailing the inclusion process, we collected
data from 970 consecutive patients who underwent a total of 1005
[123I]FP-CIT SPECT at our hospital from May 2003 to September
2013. Thirty-three subjects had two [123I]FP-CIT SPECT, and one
patient had three scans; in these cases, only the first scan was
considered for our study. Every patient was evaluated at least once
by a neurologist trained in movement disorders, except for a few
cases whose SPECT had been requested by a general neurologist. A
detailed chart review was conducted for each case, including all
available neuroimaging data. The following clinical information
was assessed and computed: age at the time of scan, gender, disease
onset, age at disease onset, symptoms, body side predominance,
and final diagnosis. Diagnoses of non-degenerative parkinsonism or
tremor were established using specific and validated sets of criteria:
the Consensus statement of the Movement Disorder Society on
tremor for essential tremor (ET) [21], the criteria proposed by
(n = 1005)
Fig. 1 Diagram showing the multiple-step procedure for
patients and DaTSCAN® inclusion in the present study
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Morgante et al. for psychogenic movement disorders [22], the
EFNS guidelines for primary dystonia [23], the clinical criteria
proposed by Zijlmans et al. [24] for vascular parkinsonism, and, for
DIP, the development of parkinsonism, preferably symmetric, in
temporal relation (use of antidopaminergic drugs in the 6 months
preceding the onset of symptoms, along with a previously negative
history for parkinsonian signs) to exposure to neuroleptics or other
drugs with antagonistic properties to dopamine receptors, was
required the more so as parkinsonian symptoms disappeared or
subsided 6 months after withdrawing the offending drug. For
degenerative parkinsonisms, clinical diagnosis was established
based on the most widely used criteria for PD [25], DLB [26],
multiple system atrophy (MSA) [27], progressive supranuclear
palsy (PSP) [28], and corticobasal degeneration (CBD) [29]. Sixty-
two patients were classified in the BUndefined^ category and thus
excluded because of incomplete data or unclear diagnosis (n=57)
or because another machine was used (n=5). A total of 908
[123I]FP-CIT SPECT from 908 different patients were eventually
included in our database.
Among these patients, we identified 201 subjects with a
diagnosis of non-degenerative condition and a normal
[123I]ioflupane SPECT defined as a grade 0 visual staging. Eight
patients were younger than 40 years old and were excluded because
this small population of young individuals was considered
irrelevant given the usually higher age range of 123I-FP-CIT
SPECT candidates. In addition, raw scan images were unavailable
for 11 patients, precluding the automatic BRASS® analysis to be
performed. By the end of the inclusion process, we were able to
collect and analyze data from a total of 182 patients older than
40 years (range 40–93) harboring a clinical diagnosis of non-
degenerative condition associated with a grade 0 SPECT, a cohort
of individuals that could be considered, from a dopaminergic point
of view, equivalent to healthy controls and therefore useful to
establish reference values.
Imaging: Data Acquisition and Reconstruction
[123I]FP-CIT SPECT was performed according to the manufac-
turer’s instructions. Patients received about 185 MBq of [123I]FP-
CIT in slow intravenous injection and were administered Lugol
solution (5 drops 5 % KI before and 4 h after injection) for thyroid
blockade. SPECT data acquisition started 4 h after administration of
the DAT tracer. Medications in general, and dopaminergic agents in
particular, whenever used, were not discontinued.
All scans were acquired on the same triple-head gamma camera
(GCA-9300A/UI Toshiba Medical Systems AG, Oetwil am See,
Switzerland) equipped with fan beam, low-energy, high-resolution
collimators. In all cases, the head was fixed in a head-holder to
minimize motion artifacts. Acquisition parameters included step-
and-shoot mode over 30 min. Sixty projection angles were taken
over 360° and a 128×128 matrix was used. Reconstruction was
done using filtered back projection by means of the manufacturer’s
software, with a Shepp and Logan filter cutoff at the Nyquist
frequency.
Uniform Chang attenuation correction was performed to
compensate for photon attenuation, using the theoretical mean
attenuation coefficient of soft tissues for 159 keV 123I photons
(0.15 cm2) and a triple-energy window method for scatter
correction [30].
Image Processing and Analyses
[123I]FP-CIT SPECT images were analyzed visually using a
previously validated semi-quantitative four-point scale, classifying
the study as normal (grade 0) or abnormal grades 1, 2, and 3 [3].
We added an in-house intermediate grade (between normal and
grade 1) to this classification indicating doubtful findings, a
questionable asymmetry, despite a good visualization of both
striata, or a lower signal-to-background contrast with preserved
Bcomma-shaped^ and symmetrical uptake.
Quantification of uptake was based on six striatal volumes of
interest (VOIs), including the right and left C, P, and S,
respectively. The regions were manually drawn on a summed
image including the whole striatum, providing measures of mean
count concentration in each striatal region (Cs). On the same image,
a VOI including the occipital cortex was drawn, providing
quantification for non-specific background mean counts (Cb). We
used these values to calculate striatal uptake ratios defined as [(Cs−
Cb)/Cb].
The regions were manually drawn over the expected C and P
distribution, even when the uptake was confined to the C. Figure 2a
provides an example of the manual drawing in a normal and in a
grade 2 (Fig. 2b) study.
Fig. 2 Selected DaTSCAN® images from two individual
studied using the manually delineated ROIs method. a
Patient with ET and a normal (grade 0) scan; b patient with
PD and an abnormal scan (grade 2). c Example of an
automated BRASS® analysis of a grade scan (same patient
as in a).
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In addition, DaTSCAN® images were quantitatively analyzed
using BRASS™ automated functional brain analysis software
(Hermes BRASS software, Nuclear Diagnostics AB, Sweden) [31].
Briefly, BRASS® software spatially coregisters the patients’
tomographic data to a 3D reference template in a standard space,
and then applies a predefined template VOI set [10, 32]. Regional
mean counts in striatal and background occipital VOIs are used to
calculate striatal uptake values [31, 33] (Fig. 2c).
Outcomes
We aimed at evaluating reference values for the following
outcomes: (1) C, (2) P, and (3) S uptake on both sides, (4) the C/
P ratio, and the asymmetry index (AI) for right and left C, P, and S.
The three VOI uptakes were defined as the mean value of the
left and right side measures, the C/P ratio as the mean of the two
ratios determined in the right and left side, and the three asymmetry
indices were determined according to a slightly modified version of
Zijlmans [24] formula [(R−L)/(R+L)]×2×100, where R deter-
mined the side with the higher uptake and L the side with the lower
uptake, in order to obtain a positive value.
Finally, the reference limits were defined as the 5th percentile
for the C, P, and S uptakes, and the 95th percentile for the C/P ratio
and the three AIs.
Statistical Analyses
Reliability and Agreement Analyses Reliability and agreement
between manual and BRASS® methods were assessed for the C
and P outcomes using intraclass correlation coefficient (ICC (3, 1)
of Shrout and Fleiss), percentage of agreement, and Bland-Altman
plot. Both reliability and agreement were not satisfactory, and we
therefore decided to use the BRASS method measures to define
reference values. The reliability and agreement of the S was not
assessed because its delineation overlapped that of the C and P.
Age and Gender Effect A possible relationship between patient
demographic parameters (age and gender) and outcomes of interest
was evaluated using graphical representation, Student’s t tests, and
linear regression analyses. Normality of outcomes was assessed
using Normal Q-Q plots. It was satisfactory for the C, P, and S
distribution whereas a box-cox power transformation method was
applied to normalize the distribution of the C/P ratio and
asymmetry indexes.
Reference Values For C, P, and S outcomes, reference values
were estimated so that 5 % of the sample has lower values (5th
percentile); for the C/P ratio and the three AIs, reference values
were estimated so that 5 % of the sample has higher values (95th
percentile). All reference values are reported with their correspond-
ing 95 % confidence interval (95 %CI). Hence, we considered that
any scan performed in our center following the same protocol
should raise the possibility of nigrostriatal dopaminergic dysfunc-
tion when VOIs uptake values are below the 5th percentile and/or
when C/P ratio and AIs are above the 95th percentile.
As gender effect was not supported by our data, we decided to
establish reference values without distinction of gender. When a
linear effect of age could not be justified, as was the case for C/P
ratios and AIs, we estimated the reference value and 95 % CI as the
5th or 95th (depending on the outcome) percentile calculated on the
sample mean and standard deviation, assuming normality. The
estimates obtained on the normalized distributions were then back-
transformed on their original scale. When a linear effect was
justified by our data, as was the case for the other outcomes, we
verified that the standard deviation of the linear regression residuals
were constant and do not depend on age (homoscedasticity). The
reference values were finally set as the regression line vertically
shifted by the value of the estimated 5th (or 95th as according to
outcome) percentile of the residuals; percentile (and 95 % CI) was
calculated based on the residuals mean and standard deviation,
assuming normality.
All analyses were performed on R-3.1.0 (R foundation for
Statistical Computing, Vienna, Austria. URL http://www.R-
project.org), except the percentile estimation which was performed
on Stata 13.0 (StataCorp. 2013. Stata Statistical Software: Release
13. College Station, TX: StataCorp LP).
Results
DaTSCAN® data from 182 patients (109 (60 %) women,
mean age 69.1±11.2 years, range 40 to 93 years) with a
normal (grade 0) visual dopaminergic uptake and a non-
degenerative condition were collected. Final clinical diag-
noses included ET (N=38), DIP (N=80), PP (N=31),
primary focal and generalized dystonia (N=8), and various
conditions unassociated with parkinsonism (N=25). Medi-
cations were not discontinued with the exception of DIP
cases where the offending agent, such as neuroleptics or
calcium-channel blockers, was stopped several weeks prior
to the scan. Twelve patients were deceased by the end of
2013, among which only one had an autopsy, confirming the
absence of any neurodegenerative process.
Comparison Reliability and Agreement of Manual
and BRASS Methods Analysis
Mean values for C, P, S, C/P ratios and AIs are available in
Table 1. When comparing the C, P, and S values provided by
the two quantification methods, ICC reliability coefficients
were 0.37 (95 % CI [0.24–0.49]), 0.38 (95 % CI [0.25–0.50]),
and 0.40 (95 % CI [0.27–0.51]), respectively (Fig. 3a–c).
Moreover, Bland-Altman plots (Fig. 3d, e, f) reveal important
bias with 64, 70, and 69 % of the absolute differences between
the two methods higher than 0.5 and 30, 36, and 27 % of the
absolute differences even higher than 1 for the C, P, and S,
respectively. The manual method showedmany disadvantages:
it was time-consuming, required specific expertise and the
manual drawing of ROIs may have led to problematic
repeatability. For example, mean C values were similar using
both methods, possibly because this particular structure is
easier to draw compared to the more complex shape of the P.
Indeed, mean putaminal values show significant differences
between the twomethods (2.39±0.78 for the manual method vs
3.04±0.51 with BRASS, pG0.001), corresponding to a 27 %
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difference. Consequently, striatal values, which are
superimposed to those from C and P, may also suffer from
this examiner-dependant method. In addition, standard
deviations obtained with the manual method are higher than
with the BRASS method, which is in line with a potentially
poorer repeatability of the former. For all these reasons, the
Table 1. Uptake values for right and left striatum, caudate nucleus, and putamen, C/P ratios, asymmetry indexes, calculated using the manual method based
on VOIs and the automated BRASS method, according to gender
Manual BRASS
All (n=182) Female (n=
109)
Male (n=73) Pval All (n=182) Female (n=
109)
Male (n=73) Pval
Striatum Right 2.66±0.77 2.69±0.84 2.60±0.65 0.413 3.19±0.52 3.25±0.56 3.09±0.45 0.035
Left 2.65±0.76 2.68±0.82 2.60±0.67 0.467 3.18±0.51 3.22±0.54 3.11±0.46 0.151
Average 2.65±0.76 2.69±0.82 2.60±0.66 0.437 3.18±0.51 3.24±0.54 3.10±0.45 0.072
Caudate
nucleus
Right 3.21±0.98 3.26±1.03 3.13±0.91 0.393 3.44±0.57 3.52±0.60 3.32±0.51 0.016
Left 3.18±0.95 3.22±1.00 3.12±0.89 0.485 3.30±0.57 3.36±0.60 3.22±0.51 0.092
Average 3.20±0.96 3.24±1.01 3.13±0.89 0.433 3.37±0.55 3.44±0.58 3.27±0.48 0.033
Putamen Right 2.40±0.81 2.43±0.88 2.36±0.70 0.576 3.00±0.54 3.05±0.57 2.92±0.47 0.102
Left 2.38±0.77 2.39±0.80 2.35±0.73 0.698 3.08±0.52 3.12±0.55 3.03±0.47 0.275
Average 2.39±0.78 2.41±0.83 2.36±0.70 0.629 3.04±0.51 3.08±0.54 2.98±0.45 0.155
C/P ratio Right 1.36±0.20 1.37±0.20 1.34±0.21 0.310 1.16±0.14 1.16±0.13 1.15±0.15 0.423
Left 1.36±0.18 1.36±0.17 1.35±0.19 0.661 1.08±0.13 1.09±0.14 1.07±0.11 0.298
Average 1.36±0.17 1.37±0.16 1.35±0.18 0.401 1.12±0.10 1.12±0.11 1.11±0.10 0.227
Assymetry (%) Striatum 4.66±4.19 4.89±4.39 4.33±3.86 0.368 4.65±3.84 4.88±4.06 4.31±3.50 0.314
Caudate 6.31±4.58 6.51±4.88 6.01±4.10 0.463 7.93±6.92 8.15±6.78 7.59±7.16 0.601
Putamen 7.58±6.94 7.72±7.22 7.36±6.55 0.724 7.46±7.12 7.31±7.06 7.69±7.27 0.726
Pval indicates the statistical significance between both methods. Values are mean±SD
Fig. 3 Comparisons of BRASS® and manual methods. a Caudate nucleus, b putamen, and c striatum BRASS® values are
shown as a function of manually obtained values. For each parameter, differences between the two methods as a function of
the mean value of the two methods are represented in d–f, respectively (Bland-Altman plot). Differences are large and not
symmetrically distributed around 0, indicating disagreement between the two methods. Data are the average of right and left
sides.
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BRASS method was here considered more convenient and
suitable to estimate our reference values.
Uptake Values, C/P Ratio, and AIs
As detailed in Table 1, we found a BRASS-derived mean
uptake value of 3.18±0.51 for the S, 3.37±0.55 for the C,
and 3.04±0.51 for the P. In addition, we calculated a mean
C/P ratio of 1.12±0.10. The AI varied depending on the
structure considered: 4.65±3.84 for the whole S, 7.93±6.92
for the C, and 7.46±7.12 for the P. Values obtained with the
manual method are detailed in Table 1.
Analysis of diagnostic subgroups of non-degenerative
parkinsonisms shows similar results for mean C, P, and S
uptake values (p90.05), as well as AIs (p=0.45) and C/P
ratio (p=0.80). Results are available in Table 2.
Gender Effect
When comparing uptake values, C/P ratio and AIs between
men and women, most of the differences were not
statistically significant (Table 1). Considering the mean of
right and left sides, only the mean difference of the C
between men and women was statistically significant (3.27±
0.48 vs 3.44±0.58, respectively, p=0.033 (Student’s t test)).
Figure 4 represents the uptake values for men and women as
a function of age. No interaction was found between age and
gender (results not shown).
Age Effect
We found a consistent decrease of uptake for all VOIs with age, at
least in the age range considered, i.e., 40 to 93 years, and this
trend was statistically significant (pG0.001). This decrease
appeared linear with a loss per decade estimate of 0.22 (SE=
0.03) for the P and S, and 0.21 (SE=0.03) for the C. We failed to
find any age effect for C/P ratio and AIs, as shown in Table 3.
Reference Values
Weestimated reference valueswithout distinction of gender as our
data showed limited evidence of a gender effect. Reference values
were estimated as a function of age for all VOIs, and the
resulting lines above which a value is considered normal
are presented in Fig. 5. A single reference value was
estimated for the C/P ratio and AIs as we had no
evidence of an age effect on these parameters. The
resulting reference values of the C/P ratio and striatum
AI, back-transformed on their original scale, are present-
ed in Fig. 5.
Discussion
To overcome the lack of reference values available for
routine DaTSCAN® interpretation, we propose in this study
an original approach that can be easily replicated and used in
any individual nuclear medicine center. Rather than relying
on values calculated at other centers using different SPECT
machines and protocols or on data obtained from brain
phantoms or from healthy controls, we examined a large
cohort of patients with various non-degenerative conditions
known and confirmed to be associated with a normal scan.
All were scanned on the same machine following the same
protocol, and images were analyzed using two distinct
quantitative methods, one based on manually drawn VOIs
and another, automated one, the BRASS® method. Because
the automated approach is rapid and more convenient and
because we suspect it having a better repeatability, we used
this method to establish reference limits of common
parameters, including uptake values of striatal nuclei, C/P
ratios, and AIs. Values outside these limits strongly support
an altered nigrostriatal system.
We analyzed the effects of age and gender on all
outcomes, and our results showed a significant linear effect
of age on C, P, and S uptake values, as already reported by
others [16, 17, 34–37]. Based on this assessment, it can be
estimated that a DaTSCAN® can be labeled as normal in our
center when the uptake is above 3.78883−(0.02156×age)
Table 2. Mean uptake values, C/P ratio, and striatum AI (expressed mean±SD) in the different non-degenerative parkinsonisms
Group Mean striatum
uptake
Mean caudate
nucleus uptake
Mean putamen
uptake
Mean C/P
ratio
Mean striatum
AI %
Drug-induced parkinsonism (n=80, M/F
ratio 0.60, age 69.9±11.1, range 41–86)
3.10±0.50 (range 1.83–4.26) 3.28±0.53
(1.88–4.43)
2.97±0.50
(1.8–4.18)
1.10±0.13
(0.69–1.50)
5.1±3.9
(0.1–19.3)
Essential tremor (n=38, M/F ratio 1.38, age
71.1±9.7, range 44–86)
3.29±0.46 (2.58–4.30) 3.49±0.47
(2.68–4.39)
3.14±0.48
(2.28–4.30)
1.12±0.14
(0.91–1.49)
4.2±2.8
(0.5–10.3)
Psychogenic parkinsonism (n=31, M/F
ratio 0.34, age 63.7±12.1, range 42–93)
3.35±0.52 (2.28–4.09) 3.55±0.59
(2.41–4.39)
3.21±0.49
(2.19–3.94)
1.11±0.13
(0.87–1.51)
4.1±2.5
(0.1–10.8)
Dystonic tremor (n=8, M/F ratio 0.60,
age 62.3±14.2, range 42–79)
3.34±0.64 (2.35–4.32) 3.53±0.57
(2.61–4.34)
3.20±0.70
(2.16–4.30)
1.12±0.11
(0.95–1.27)
2.8±2.4
(0–7.4)
Others (n=25, M/F ratio 0.67, age
72.2±8.6, range 49–86)
3.01±0.49 (1.99–3.89) 3.22±0.59
(2.30–4.35)
2.86±0.46
(1.77–3.65)
1.14±0.16
(0.91–1.54)
5.3±6.1
(0–22.3)
p Valuea 0.057 0.054 0.096 0.808 0.451
ap Values are adjusted for age and gender
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for the S, 3.87465−(0.02141×age) for the C, and 3.65557
−(0.02168×age) for the P. For example, a healthy 70-year-
old individual is expected to exhibit values above 2.27 for
the S, 2.37 for the C, and 2.13 for the P on each side. Linear
regression analysis showed an age-related decline that was
consistent and very similar across the three structures, with a
mean decline of −0.21 per decade for the C and of −0.22 for the
P and C. Of note and at variance with other authors, we
estimated a constant decline per decade rather than a decreasing
decline per decade. Indeed, when other authors report a percent
decline per decade, they do the assumption that the loss will be
non-linear, smaller between 60 and 70 than between 50 and
60 years old.We found that our data (with an age range from 40
to 93 years) do not support such a relation but rather a linear
relation. Nonetheless, we calculated a mean decline over our
whole population of 6.8 % (striatum), 6.5 % (caudate nucleus),
and 7 % (putamen) per decade, which is consistent with what
has been reported in the currently available literature on healthy
controls (between 4 and 9 % per decade) [16, 37–40].
With respect to a potential gender effect, our study yielded
inconclusive results, women showing slightly higher mean
values than men for all VOIs, some of them (right S, right and
mean C) being statistically significant. In previous studies [16,
36, 41–43], some hypotheses have been put forward to explain
Table 3. Linear regression analyses of all outcomes according to age
Coef SE p
Value
Caudate nucleus Intercept 4.85 0.23
Slope −0.21 0.03 G0.001
Putamen Intercept 4.54 0.21
Slope −0.22 0.03 G0.001
Striatum Intercept 4.67 0.21
Slope −0.22 0.03 G0.001
C/P ratioa Intercept 0.059 0.036
Slope 0.005 0.005 0.313
Caudate nucleus
asymmetry indexa
Intercept 1.57 0.83
Slope 0.14 0.12 0.248
Putamen asymmetry
indexa
Intercept 1.38 0.85
Slope 0.11 0.12 0.365
Striatum asymmetry
indexa
Intercept 0.60 0.66
Slope 0.15 0.09 0.111
aBox-cox transformed data
Fig. 4 Effects of age and gender upon uptake values of caudate nucleus, putamen, striatum, caudate nucleus to putamen
ratio, and striatum asymmetry index. Data are the average of right and left sides.
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why women have sometimes been found to have a higher
striatal uptake. The most likely explanation relies on an artifact
whereby a similar number of neurons—than men—project a
higher density of nerve terminals because of a relative smaller
brain volume [34, 43]. However, in most previous studies,
small samples of healthy control patients were used and this
difference tended to disappear with ageing. In fact, we
observed the same trend in our study, with an age-related
decline of all three VOIs found greater in women than men, yet
none of these differences in slope was statistically significant.
While it is possible that our study lacked power to detect
differences in slope, reasons for a stronger decline of striatal
uptake in women remain unclear. In conclusion, a gender effect
could not be excluded. However, with respect to the purpose of
our study, this led us to establish reference values identical for
both genders, the more so as other studies have failed to show
significant differences of striatal uptake in relation to gender
[44].
We also took advantage of this study to examine other
parameters that might be of interest to detect very early
parkinsonism and to differentiate between the various forms
of degenerative parkinsonism. For example, it has been
proposed that the beginning of PD may be associated with a
higher than normal asymmetry of uptake between both sides,
and PSP has been shown to exhibit lower AI and C/P ratio
than MSA or PD [45, 46]. Also, some studies have
emphasized the usefulness of AI to distinguish PD from
vascular parkinsonism [47, 48]. It therefore appeared useful
to establish reference values for these two outcomes in our
population. Regarding the C/P ratio, we found no evidence
that this parameter does change with age or gender. We
estimated the upper reference limit to be 1.35 on both sides.
Mean values are similar to that reported previously [16, 38]
and show usually clear-cut differences with PD patients,
who have a much higher C/P ratio due to early putaminal
decline [49, 50]. Similarly, we found no evidence for all
Fig. 5 Calculated reference values for the whole population, irrespective of gender. The solid line represents the reference
value(s) defined as the 5th percentile for caudate nucleus, putamen and striatum, and 95th percentile for C/P ratio and striatum
AI; the dotted lines represent the 95 %CI. Reference values depend on age for the caudate nucleus, putamen, and striatum
parameters; as data do not support an age effect on C/P ratio and striatum AI, a general reference value is given for these two
parameters.
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three AIs that they may vary according to age or gender.
Mean AIs ranged from 4 to 7 % according to the region
studied and striatum AI was here considered normal when
lower than 14.37 %. It can be therefore suggested that a
normal DaTSCAN® is associated with low AIs and
relatively low C/P ratios, irrespective of age and gender,
and values above the proposed limits potentially suggest
subtle structural abnormalities in the nigrostriatal pathway.
Comparing uptake values across studies is usually difficult,
given the many, sometimes subtle methodological differences
between centers. Previous attempts by others have included
small samples of healthy volunteers [41] or pooled data from
different centers, leading to significant differences of mean
VOIs values [16]. Besides, reference values have never been
clearly provided in previous studies. In comparison with the
results of Varrone et al. in the ENC-DAT study [16], we found
slightly higher intercepts and greater slopes (for example, 95 %
CI mean slope for striatum is −0.22 (range −0.27 to −0.16) per
decade in our study, whereas in the ENC-DAT study, −0.15
(−0.21 to −0.09) is found. Importantly, however, mean values
for caudate and putamen (male and female) were similar if not
identical, as shown in Table 1 where our data can be compared
with uncalibrated ACSC mean values from the ENC-DAT
study. This finding somewhat supports the validity of the
methodological approach proposed here.
Our study has some limitations. First, as it is the case for
most studies on this topic, diagnoses were based on clinical
criteria and final neuropathological assessment was not
available for the vast majority of included subjects.
Therefore, it may be possible that the study population was
contaminated by cases with pre-clinical degenerative condi-
tions affecting the nigrostriatal system, yet this issue is also
true for any study using healthy controls of this age
category. In our study, however, much effort was done to
minimize this problem. Nearly all patients were examined by
trained movement disorders specialists, stringent and well
accepted diagnostic criteria were applied and, perhaps more
importantly, the long duration of the study allowed most
cases to be followed over time, with those developing PD or
any other forms of degenerative parkinsonism being exclud-
ed along the study duration. In fact, the retrospective nature
of this study might be considered an advantage for the issue
of diagnostic accuracy as it may allow uncertain cases to be
reassessed over a period of time during which clinical
diagnosis may have become clearer. Second, a normal scan
was here defined as a grade 0 [123I]FP-CIT SPECT
according to the visual scale proposed by Catafau et al. [8]
and used by most authors. While the validity of this scale
has been demonstrated, there have been some controversies
regarding intrarater and interrater reproducibility, leaving
some room for interpretation and possibly some grading
misattribution in doubtful cases [51]. However, in our study,
borderline scans were clearly identified, separated from
normal scans (between grade 0 and 1) and excluded. In
addition, a normal scan was only a secondary criterion for
enrolment, the primary one being a clear clinical diagnosis of
non-degenerative condition to be fulfilled. Cases with a
questionable diagnosis and a normal scan were not included
in the study. Third, to achieve enough statistical power, a
relatively large study population is required. In our case, with a
mean recruitment of 100 scans per year, it took about 10 years
to collect nearly 200 subjects for the present study. Thus, for
the model proposed here to be replicated elsewhere, a minimal
number of scans should be performed at the center, yet
preliminary reference limits can likely be calculated already
with about 100 well-documented cases of grade 0 SPECT.
Importantly, the purpose of our study was not to provide data
applicable to other centers, but rather to propose a new method
allowing defining on-site reference values established follow-
ing the local methodological specificities.
Finally, the very usefulness of establishing precise reference
values for [123I]FP-CIT SPECT in the clinic might be a matter
of controversy, as visual interpretation is likely sufficient in
many cases to separate normal from abnormal scans. It is
however our experience that a significant percentage of
examined scans is variably interpreted, likely depending on
the expertise level of the nuclear medicine and/or movement
disorders specialists. In fact, we propose that semi-quantitative
methods of assessment complement visual interpretation rather
than substituting for it. It may even become mandatory when
assessing difficult clinical situations such as aging-related
pseudo-parkinsonism, very early degenerative conditions with
borderline scans, or patients with scan without evidence of
dopamine deficiency (SWEDD).
Conclusion
To the best of our knowledge, this is the first study to
address the issue of quantitative reference values for
DaTSCAN® parameters that can be used at the site level,
including uptake values for the C, P and S, the C/P ratios,
and AIs between both sides. We propose to analyze grade 0
scans of patients with clinically clear non-degenerative
conditions using the BRASS® method, or any validated
software, and to establish age-dependent, reference limits
based on the percentile approach. Although our results
appear robust, they now need to be tested against a cohort of
patients with degenerative forms of parkinsonism. This next
step is under way in our institution. Moreover, replication
and confirmation by independent groups are still required
before this model can be applied on a routine basis.
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